SHORT REPORTS
Family with raised serum alkaline phosphatase activity in the absence of disease Idiopathic familial raised serum alkaline phosphatase activity has been reported only once.' The prevalence and nature of this curious biochemical abnormality is unknown. We report results of genetic and isoenzyme studies in another family with this disorder.
Subjects, methods, and results
A 9-year-old boy was referred to hospital for investigation of abdominal pain. His serum alkaline phosphatase activity was over 1000 U/l. Extensive clinical, radiological, and biochemical investigations failed to account for this. Systematic survey of the whole family (figure) showed that all six siblings of the propositus (aged 8, 12, 14, 16, 18 , and 21) and his mother had abnormally high serum alkaline phosphatase activities (normal range in our laboratory up to 400 U/l for children and up to 150 U/l for adults (Technicon SMA 12/60 method) Raised plasma renin activity in the hypertension of the Guillain-Barre' syndrome Hypertension has often been observed in patients with the GuillainBarre syndrome, and various underlying mechanisms have been implicated. We report on a child with the Guillain-Barre syndrome whose hypertension was related to increased renin-angiotension activity. Treatment with propranolol controlled the hypertension effectively and reduced the raised plasma renin activity.
Case report
A 10-year-old boy had severe headache, trismus, and dysarthria of one week's duration. Vital signs showed a blood pressure of 140/100 mm Hg, pulse 84 beats/min, respirations 12/min, and temperature 37'C. Initial examination showed bilateral paresis of the facial nerves, and at this stage no other neurological signs were present. Myasthenia gravis was excluded by failure to respond to edrophonium chloride. Results of laboratory studies showed a normal erythrocyte sedimentation rate, complete blood cell count, electrolyte and serum creatinine concentrations, liver function tests, muscle enzyme activities, heavy-metal screen, and antinuclear antibody tests. Raised IgM concentrations of 420 mg/100 ml were found; IgG was 1100 mg/100 ml and IgA 130 mg/100 ml, which are within the normal range. The specific IgM titres for cytomegalovirus were 1:8 within the first week of the disease and undetectable four weeks later. Cultures of urine for the virus were negative. On admission the cerebrospinal fluid had an opening pressure of 11 cm H2O, protein was 0-2 g/l, glucose was 3-88 mmol/l (70 mg/100 ml), and no leucocytes were present. Electrocardiography and electroencephalography yielded normal results. Roentgenograms of the skull and chest and an intravenous pyelogram were also normal.
During the next 10 days a gradually progressive ascending symmetrical muscle weakness occurred without any sensory loss. A repeat spinal tap showed a protein content of 3 g/l without pleocytosis. Electromyography showed distinct slowing of nerve conduction time and no signs of denervation. These findings confirmed the diagnosis of the Guillain-Barre syndrome. Further deterioration was manifested by progressive paresis of his arms and legs, dysphagia, and a measured vital capacity of 47 % of the expected value.
Prednisone treatment was started. The figure shows the patient's course of recovery. A relapse occurred after 45 days, which also responded to prednisone.
Before the onset of paresis and throughout the course of the disease diffuse headache was prominent and sometimes debilitating. Chlorothiazide and hydralazine were ineffective in relieving the symptoms. The patient's hypertension and concomitant headache were controlled with propranolol. Plasma renin activity was raised throughout the course (range 13-0-14-8 nmol/l/h (16 9-19 2 ng/ml/h)) and eventually returned to normal (1-5 nmol/l/h (2-0 ng/ml/h)) after high doses of propranolol. Serum catecholamine concentration (150 ng/ml) and urine excretion of vanillylmandelic acid (<5 0 mg/g creatinine) were normal. During this period propranolol was stopped for 12 hours and severe headache and hypertension recurred.
Six Conversion: SI to traditional units-Plasma renin activity: 1 mmol/l/h 1 3 ng/ml/h.
Comment
Symptoms related to disease of the autonomic nervous system are common in patients with the Guillain-Barre syndrome.' It is unlikely, however, that adrenergic overactivity was responsible for the hypertension in our patient, since no tachycardia, hyperhidrosis, or peripheral vasoconstriction were noticed. In addition, no raised values of blood catecholamines or urinary excretion of vanillylmandelic acid, as observed by Mitchell and Meilman,' were found. The presence of the hypertension was closely associated with the raised plasma renin activity. Propranolol, which inhibits renin biosynthesis by the juxtaglomerular apparatus, proved particularly effective in controlling the headache and reduced the blood pressure and plasma renin activity. Only one similar case has been reported. 3 We suggest that plasma renin activity should be measured in all patients with the Guillain-Barre syndrome and hypertension, and that propranolol should be the drug of choice in the hypertension of the Guillain-Barre syndrome. 
Serum ferritin and rheumatoid disease
All inflammatory conditions affect iron kinetics. In rheumatoid arthritis this is reflected by anaemia, with variables suggestive of iron deficiency but normal iron stores within the bone marrow and excess iron within the inflamed synovial membrane. The synovial reticuloendothelial cell stores iron as ferritin1 within the protein envelope of apoferritin. The production of ferritin by the reticuloendothelial cell and concomitant rise in serum ferritin concentration may reflect the cell's attempt to protect itself from the toxic consequences of excess free intracellular iron.
Estimation of serum ferritin concentration is useful in assessing the degree of inflammation in juvenile chronic polyarthritis2 and in many other inflammatory conditions. Because of suggestions that disturbance of iron metabolism may directly affect the inflammatory process3 we studied the role of serum ferritin concentration in patients with rheumatoid synovitis and systemic rheumatoid disease.
Patients, methods, and results
Serum ferritin concentration was measured by radioimmunoassay (Gammadab 1251I ferritin kit, Travenol Lab). Two studies were performed: A cross-sectional study of 47 patients with rheumatoid synovitis and 13 with systemic complications of their disease and a longitudinal study of 150 patients presenting with early rheumatoid synovitis (total duration less than six months) and continued for 18 months through exacerbation and remission of their disease. In the first study serum ferritin concentration was correlated with two measures of inflammatory activity: clinical, Ritchie articular index (joint pain index) and duration of morning stiffness; laboratory, haemoglobin concentration, white cell count, platelet count, IgM rheumatoid factor, plasma viscosity, erythrocyte sedimentation rate, C-reactive protein, putative immune complexes (% Clq binding activity), and complement components C3 and C4. There was no significant correlation between serum ferritin concentration and any of these variables (Spearman rank correlation coefficient r 602 in each case). Mean serum ferritin concentration in the 13 patients with systemic complications, however, was three times that in the 47 patients with pure synovitis (240 v 80 [tg/l; p < 0-001).
In the longitudinal study serum ferritin concentrations were raised during episodes of active synovitis and fell with remission. Changing concentrations mirrored changes in plasma viscosity and levels of circulating immune complexes. High concentrations (>300 tLgll) were found in eight out of 10 patients who presented with, or developed, systemic manifestations and severe disease. None of the five patients with low initial concentration (S15 Hg/l) developed such complications and all had mild disease, often seronegative. A single estimation of serum ferritin concentration was no help in assessing the degree of inflammation unless contrasted with an estimation performed during a period of remission, which accounts for the lack of correlation in the cross-sectional study.
Comment
Serum ferritin concentrations fluctuate during episodes of inflammation, the percentage change within the individual rather than the absolute concentration reflecting the degree of inflammation. Consequently serum ferritin concentration may be used to monitor inflammatory activity only if serial measurements are made. An initial high concentration in patients presenting with early rheumatoid arthritis is a poor prognostic index associated with either the presence of, or development of, systemic complications and severe disease.
That iron may have a direct role in worsening the inflammatory process is supported by the observations that high ferritin concentrations are associated with systemic disease and that patients with low concentrations do not appear to develop such complications. Iron may promote inflammation by catalysing free oxygen radical production,3 which may adversely affect reticuloendothelial metabolism. Genuine iron deficiency reflected by a low serum ferritin concentration may therefore protect against such complications. This may explain why men, with their greater iron stores, are more likely to develop the most severe systemic complications of this disease, which have recently been suggested to be due to reticuloendothelial cell dysfunction.4 Intravenous iron infusion in patients with established rheumatoid inflammation may be associated with exacerbation of the disease.5
Iron in the development of systemic rheumatoid disease merits further investigation. 
